Loading...
Loading...
ADIL| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.1K |
| Gross Profit | -0.1K |
| Operating Expense | 1,477.4K |
| Operating I/L | -1,477.4K |
| Other Income/Expense | -32.5K |
| Interest Income | 19.4K |
| Pretax | -1,509.9K |
| Income Tax Expense | -2,597.7K |
| Net Income/Loss | 1,087.8K |
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutics for addiction and related disorders. Its primary revenue driver is AD04, a selective serotonin-3 antagonist currently in Phase III clinical trial for alcohol use disorder treatment. The company also focuses on non-opioid pain reduction and other drug candidates for various diseases and disorders.
